SCHEMBL24763412

SCHEMBL24763412

O=C(N1CCN(C2(c3ccc(SCc4ccccc4)cc3)COC2)CC1)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 6/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HTT P42858 3/20 0.37
▸ CHRM1 P11229 3/20 0.35
▸ CHRM4 P08173 1/20 0.35
▸ CHRM5 P08912 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ MCL1 Q07820 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ FKBP1A P62942 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24762050 0.90 LMNA (0.41) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL27238568 0.79 MAPK1 (0.36) LMNAKMT2AALDH1A1SMN1; SMN2CHRM1
SCHEMBL24763409 0.77 AKR1C3 (0.36) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL24763407 0.77 AKR1C3 (0.36) MAPK1
SCHEMBL24762182 0.74 PKM (0.55) LMNAKMT2AALDH1A1NPC1PKM
SCHEMBL24762229 0.73 RORC (0.33) PKML3MBTL1
SCHEMBL24762619 0.72 HTR2A (0.45) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL29799563 0.72 PPARG (0.41) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL24763408 0.71 KDM1A (0.47) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL24762200 0.70 LMNA (0.42) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2024-06-13 — — US disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 — — WO disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF PACSIN2, TPX2, PRSS12 LMNA 2712/4885KMT2A 4619/4885MEN1 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback